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Abstract  
BACKGROUND: Papillary thyroid carcinoma (PTC) accounts for 80% of the thyroid malignancies that are 
characterised by slow growth and an excellent prognosis. Over-expression of SMAD4 protein restores TGF-β 
signalling, determines a strong increase in anti-proliferative effect and reduces invasive potential of tumour cells 
expressing it.  
AIM: The study aimed to analyse the immunohistochemical expression of TGF-β1 and its downstream 
phosphorylated SMAD4, element and of the inhibitory SMAD7 PTC variants and their association with the 
localisation of TAMs within the tumour microenvironment.  
METHODS: For this retrospective study we investigated 69 patients immunohistochemistry with antibodies 
against TGF-β, TGF – β-RII, SMAD4, SMAD7, CD68+ macrophages.  
RESULTS: Patients with low infiltration with CD68+ cells in tumour stroma has significantly shorter survival 
(median of 129.267 months) compared to those with high CD68+ cells infiltration (p = 0.034). From the analysis of 
CD68+ cells in tumour border and tumour stroma correlated with expression of TGF-β1 / SMAD proteins, we 
observed that the positive expression of TGF-β1 in tumour cytoplasm, significantly correlated with increased 
number of CD68+ cells in tumour border (X
2
 = 5,945; р = 0.015).  
CONCLUSION: TGF-β enhances motility and stimulates recruitment of monocytes, macrophages and other 
immune cells while directly inhibiting their anti-tumour effector functions. 
 
 
 
 
 
 
 
 
Introduction 
 
The transforming growth factor beta (TGF-β) 
impact on the immune system and tumour 
progression has been studied in general and in the 
development of thyroid cancer [1] [2] [3] [4] [5]. TGF-β 
activation is induced by several mechanisms including 
the expression of αvβ6 integrin, chymase, elastase, 
MMP9 etc. [6] [7] [8]. Activated TGF-β, after binding 
the TGF-β receptor II (TGF-RII) efficiently trans -
activates TGF-β receptor I (TGF-RI) and directly 
promotes tyrosine phosphorylation [9]. Then TGF-β 
signalling activates R-Smads (SMAD2 and SMAD3 
localised in the cytoplasm), through phosphorylation 
and after that allows the assembly of complexes with 
SMAD4. These complexes re-localise to the nucleus 
where they can regulate gene transcription [10]. This 
is the active TGF–β/SMAD–dependent pathway [2]. 
On the opposite, SMAD7 antagonises TGF–β/Smad – 
dependent signalling, and induces TGF-β receptor 
degradation and thus preventing SMAD2 and SMAD3 
phosphorylation. SMAD7 leads a loss of TGF–
β/SMAD-dependent pathway growth inhibition [10]. 
Normally and in the early phase of cancer 
TGF–β/SMAD-dependent pathway signalling inhibits 
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epithelial or cancer cell proliferation, and sometimes 
migration and invasiveness. These processes are 
studied in some cases with papillary thyroid cancer 
(PTC) [2] [11]. 
In late phases tumour cells overcome TGF-β-
induced suppressor effects on cell proliferation, an on 
the other hand tumour cells themselves may respond 
to this cytokine including other effects that contribute 
to tumour progression such as epithelial-
mesenchymal transition (EMT), invasion and 
metastases [1] [3]. TGF-β modulates the immune 
response that shields a tumour from immune 
surveillance [12] [13].  
PTC accounts for 80 % of the thyroid 
malignancies that are characterised by slow growth 
and an excellent prognosis. However, 10–15 % of 
cases exhibit aggressive behaviour with hallmarks of 
local invasion, distant metastases, treatment 
resistance, and motility [14] [15]. 
TGF-β1 normally expressed and secreted by 
normal thyrocytes is a potent inhibitor of thyroid cell 
growth [16] [17]. In tumours, TGF-β expression has 
been detected in 52-100% of PTC cases [18]. SMAD4 
is found to be expressed in 75% of PTC cases [11] 
[19] and every PTC cell line [19]. The SMAD7 
expression has been detected in 80% of PTCs and 
PTC cell lines [11] [20]. It has been found that 
TGFβRII mRNA transcripts are mainly expressed in 
55% of PTCs compared to other thyroid cancers [21]. 
However, TGFβRII protein and mRNA expression 
display reduced levels in thyroid cancer cells [17] [21].  
 TGF-β is abundant in the tumour 
microenvironment. It stimulates all cell populations 
including tumour cells, fibroblasts, and endothelial 
cells. Moreover, it enhances motility and recruitment 
of immune cells including monocytes, macrophages, 
NK cells, dendritic cells and T-cells while directly 
inhibiting their anti-tumour functions [22] [23]. 
We decided to analyse the 
immunohistochemical expression of TGF-β1 and its 
downstream phosphorylated SMAD4, element and of 
the inhibitory SMAD7 in PTC variants and their 
association with the localisation of TAMs within the 
tumour microenvironment.  
 
 
Material and Methods 
 
Tumor samples 
A series of 69 PTC cases has been retrieved 
from the Archives of the University Hospital in Stara 
Zagora, Bulgaria. The group of patients with PTC 
include cases with lymph node metastases (n = 2 or 
2.9%) and without metastases and without 
metastases (n = 67 or 97.1%). The mean follow-up of 
152.58 months; range from 1.64 to 197.07 has been 
done. PTC tumours were classified by size into 
tumours 1cm or less in greatest dimension and 
tumours more than 1cm in greatest dimension. There 
are 9 (13.0%) men and 60 (87.0%) women with age 
ranging from 22 to 81 years (mean 51.84 ± 13.756). 
Among the 69 PTC studied, 6 are ≤ 1 cm in diameter, 
and 63 tumours are larger. According to AJCC 
classification [24], 42 of the patients (60.8%) are in 
stage I, 20 of the patients (29.0 %) are in stage II, 7 of 
the patients (10.2%) are in stage III, and no patients 
are in stage IV of the disease, (Table 1). 
Table 1: Demographic, clinical data, histological and 
pathological characteristics of the tumour specimens 
according to the papillary thyroid tumour type 
Characteristics PTC N (%) 
Age (mean ± SD) 54.17 ± 14.48 
Gender 
Males 
Females 
 
9 (13.0) 
60 (87.0) 
Pt classification 
T1-T2 
T3-T4 
 
64 (92.7) 
5  (7.3) 
Lymph node metastases 
N0 
N1 
 
67 (97.1) 
2 (2.9) 
Distant metastases 
M0 
M1 
 
69 (100) 
0 (0) 
Ptnm staging 
I stage 
II stage 
III stage 
IV stage 
 
42 (60.8) 
20 (29.0) 
7 (10.2) 
0 (0) 
Differentiation 
Well 
Poorly 
 
69 (100) 
0 (0) 
Capsule 
Non 
Presence 
 
9  (13.0) 
60 (87.0) 
* - ANOVA test; ** - 2 test. 
 
The study protocol has been approved by the 
Research Ethics Committee of University Hospital 
Stara Zagora. 
All samples have been fixed in formalin and 
embedded in paraffin. Clinical data has been collected 
from the pathology reports, clinical files and Oncology 
Dispensary. H&E slides are retrieved from the 
archives, and they have been reviewed independently 
by two pathologists (MG and KI), and the tumours are 
classified using the WHO criteria [25]. Cases with 
doubtful PTC features are excluded. 
 
Immunohistochemistry 
Immunohistochemical staining is performed 
using the streptavidin-biotin technique as previously 
described [26]. Briefly, the endogenous peroxidase is 
blocked with 3% hydrogen peroxide in methanol for 10 
min. Slides are incubated over night at room 
temperature with primary antibodies as follows: TGF -
β (Clone sc-146) antibody in a dilution 1:50; 
monoclonal mouse anti-SMAD4 antibody (Clone sc -
7966) in a dilution 1:100; monoclonal mouse anti-
SMAD7 antibody (Clone sc-11392) in a dilution 1:100; 
monoclonal mouse anti-TGFβ RII antibody (Clone sc-
400) in a dilution 1:100-all produced from Santa Cruz 
Biotechnology, CA and monoclonal mouse anti-CD68 
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antibody (Clone KP11 M0814) ready–to-use, has 
been purchased from DAKO, Glostrub, Denmark. 
Then the slides are incubated with biotinylated 
secondary antibody and streptavidin-peroxidase 
complex for 2 hours and room temperature. Tissue 
sections with adequate positive and negative controls 
are used in every set of straining. Finally, sections are 
weakly counterstained with Mayer’s hematoxylin.  
 
Semi-quantitative assessment of TGF-β1, 
SMAD4, SMAD7, and TGFβRII  
The TGF-β1 expression is evaluated in the 
cytoplasm of tumour cells, TGFβRII expression is 
evaluated in tumour cell cytoplasm and membrane. 
SMAD4 and SMAD7 are evaluated in tumour cell 
cytoplasm and tumour cell nucleus. The 
immunohistochemical expression is evaluated as 
absent (0) and present (+) in tumour cell cytoplasm 
and nuclei. The TGF-β1 expression is also evaluated 
in the centre and periphery of all thyroid cancers 
(PTC) and in the respective remaining thyroid tissue, 
which has been used as an internal control. TGF-β1 
expression, detected in thyrocytes in the control tissue 
is considered as the basal expression. 
The expression of SMAD4 and SMAD7 is 
evaluated in all PTCs and in the respective remaining 
thyroid tissue, which has been used as an internal 
control tissue and considered as a basal expression. 
The expression of SMAD4 and SMAD7 has been not 
evaluated in the centre and periphery since it is 
considered too difficult to distinguish and therefore 
assumed as similar. Their expression is also 
graduated in two categories: absent and present 
(weak, moderate and intense staining) regarding each 
subcellular location (nuclear and cytoplasmic) 
separately. 
 
Macrophage counting 
 A single pathologist (MG), who is blinded to 
the clinical assessments of each case, has scored the 
cases by counting, the number of CD68 TAMs in five 
independent fields of vision in a tumour and the 
invasive front under a 400 x magnification. CD68
+ 
cell 
counts are expressed as the mean ± standard 
deviation. 
 
Patients’ slides with PTC assessed 
parameters 
Clinicopathological parameters. On H&E 
slides the following parameters are evaluated: capsule 
formation, capsule infiltration, vascular invasion and 
from protocols – extra-thyroid extension, metastases, 
multicentricity and tumour size of micro-carcinomas 
are checked. Patients are followed up until January 
2016. 
 
Statistical analysis 
The SPSS 16.0 program for Windows was 
used for statistical analysis. The chi-squared test and 
Fisher’s exact test were used to compare the 
immunohistochemical staining and the 
clinicopathological parameters. ANOVA, Student – t-
test, Mann-Whitney U test and Kruskal-Wallis test 
were applied for comparing the continuous variables 
depending on the normality of the distribution. 
Correlations were tested by Spearmen and Person 
tests. Survival plots were drawn by the Kaplan–Meier 
test and survival periods were compared by log-rank 
test. The accepted level of significance was set at p < 
0.05. 
 
 
Results 
 
Components of TGF-β1 pathway in tumour 
tissue  
The TGF-β1 expression is detected mainly in 
tumour cell cytoplasm and is weakly demonstrated in 
tumour cell membranes. As compared to TGF-β1 
expression, TGFβRII immune reaction is weaker in 
tumour cell cytoplasm (17.8%). 
 
Figure 1: Positive expression of TGF-β1 in tumour border (х 100) 
 
The TGF-β1 expression is not significantly 
correlated to any other clinical or pathological 
parameters. The cytoplasmic expression of TGF-β1 is 
directly proportional to the expression of both SMAD4 
and SMAD7. 
 
Figure 2: Positive expression of TGF-β1 in tumour cytoplasm and tumour 
border in micro-papillary thyroid cancer (х 100) 
 
Lack of expression of TGF-β1 and SMAD7 in 
tumour cell cytoplasm is associated with capsule 
formations around tumour tissue. The SMAD4 nuclear 
expression is observed in 8.1% (n=4 patients) of 
tumours. There is not a significant difference between 
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TGF-β1 expression at the periphery of each a tumour 
and in its centre. 
 
Figure 3: TGFβRII positive, strong expression (x 200) 
 
The expression of SMAD4 and SMAD7 in 
tumour nuclei is insignificant. The SMAD4 strong 
cytoplasmic expression is observed in 11 patients 
(24.4%) and weak positivity in 26 patients (57.8%).  
 
Figure 4: Positive expression of Smad4  in tumour nuclei (х 100) 
 
The SMAD7 strong cytoplasmic expression is 
observed in 3 patients (6.7%) and weak positivity in 
27 patients (60%). TGF-β1, TGFβRII, SMAD4 and 
SMAD7 cytoplasmic expression is not significantly 
associated with any clinical or pathological 
parameters, (Figure 1-5).  
 
Figure 5: Strong positive expression of Smad7 in tumour cytoplasm (х 200) 
 
Characterization of TAMs in PTC 
The CD68 immunohistochemistry effectively 
stains macrophage cytoplasm. The TAM nuclei in 
PTC tissue are approximately 1/3 to ½ of the size of 
the nuclei of tumour cells. TAMs had cellular 
projections that wrap around tumour cells. TAMs and 
cancer cells appeared to be in close contact (Figure 
6). TAMs formed distinctive canopy-like structures 
over some tumour cells. 
 
Figure 6: CD68-positive macrophages with canopy-like structures (x200) 
 
Correlations between clinic-pathologic 
parameters, TGF-β1, TGFβRII, SMAD4 and 
SMAD7and CD68-positive TAM densities  
As histologic grade (type) of thyroid cancer is 
an important determinant of tumour behaviour and 
clinical prognosis, it is important to explore the effect 
of TAMs and TGF-β1 signalling pathway proteins on 
some clinic-pathologic parameters. There is no 
statistical correlation between the presence of TAMs 
(high or low density) and extra-thyroidal extension, 
capsular invasion and vascular invasion. The intense 
TGF-β1, SMAD4 and SMAD7 expression in tumour 
cell cytoplasm correlated with increased CD68+ TAMs 
number in tumour stroma (and for TGF-β1 in the 
invasive margin). There were no differences between 
patients with or without increased CD68- positive 
TAMs in gender, age, tumour stage and grade (Table 
3).  
Table 2: Associations between the presence of CD68-positive 
cells in tumour border and the invasion front of tumours with 
the expression of molecules involved TGF-β1 signalling 
pathway 
Expression level 
of TGF-β1 
signalling pathway 
molecules 
№ CD68 in tumour border 
N (%) 
CD68 in tumour stroma 
N (%) 
 
 
 
 Low numbers 
(less than 5.57-
50
th
 percentile) 
  High numbers 
(less than 5.57-
50
th
 percentile) 
Low numbers 
(less than 
11.80-50
th
 
percentile) 
High numbers 
(less than 
11.80-50
th
 
percentile) 
TGF-β1 in tumour 
stroma 
    Negative n (%) 
    Positive n (%) 
 
 
17 
34 
  
 
  3 (17,64) 
 21 (52,5) 
 
  
14 (82,35) 
19 (47,5) 
  
 
  9 (52,94) 
20 (58,82) 
  
 
  8 (47,05) 
14 (41,17) 
P value  0.015* 0.689 
TGF-β1 in tumour 
border 
    Negative n (%) 
    Positive n (%) 
 
 
22 
29 
  
 
  8 (36,36) 
16 (55,17) 
  
 
14 (63,63) 
13 (44,83) 
  
 
5 (50,00) 
24 (58,53) 
  
 
5 (50,00) 
17 (41,47) 
P value  0.183 0.625 
SMAD4  in tumour 
stroma 
    Negative n (%) 
    Positive n (%) 
 
 
17 
34 
  
   
7 (41,17) 
17 (70,83) 
  
 
10 (58,82) 
  7 (29,16) 
  
 
10 (58,82) 
19 (55,88) 
  
  
 7 (41,17) 
15 (44,12) 
P value  0.058** 0.842 
SMAD4 in tumour 
border 
     Negative n (%) 
     Positive n (%) 
 
 
27 
14 
  
 
15 (40,45) 
  9 (64,28) 
  
 
22 (59,45) 
  5 (35,71) 
  
 
10 (55,55) 
19 (57,57) 
  
   
8 (44,44) 
14 (42,42) 
P value  0.129*** 0.889 
SMAD7  in tumour 
stroma 
     Negative n (% 
     Positive n (%) 
 
 
30 
21 
  
 
13 (43,33) 
11 (52,38) 
  
 
17 (56.66) 
10 (47,61) 
  
 
18 (60,00) 
11 (52,38) 
  
 
12 (40,00) 
10 (47,61) 
P value  0.524 0.589 
SMAD7 in tumour 
border 
     Negative n (%) 
     Positive  n (%) 
 
 
25 
26 
  
 
17 (68,0) 
12 (46,15) 
  
   
8 (32,0) 
14 (53,84) 
  
 
15 (60,0) 
  9 (34,61) 
  
 
10 (40,0) 
17 (65,38) 
P value  0.069** 0.115*** 
X
2 
- test: * The values in bold shown statistical significance; ** Values in bold italic shown 
(border) importance; *** The values in italic shown tendency. 
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From the analysis of CD68- positive cells in 
tumour border and tumour stroma correlated with 
expression of TGF-β1/SMAD proteins, we observed 
that the positive expression of TGF-β1 in tumour 
cytoplasm, significantly correlated with increased 
number of CD68-positive cells in tumour border (
2
 = 
5.945; р = 0.015). Our work also revealed marginal 
significantly of Smad4 in tumor cytoplasm as 
compared to increased number of macrophages in 
tumor border (
2
= 3.606; р = 0.058), and a tendency 
for Smad7 in tumor border correlated with increased 
number of CD68-positive cells in tumor stroma (p = 
0.115), (Table 2 and 3). 
Table 3: Association between various clinic-pathological 
factors with the number of CD68-positive cells in tumour 
stroma and tumour border 
Characteristics № CD68+ cell in 
tumour stroma 
mean ± SD 
P value CD68+cell in 
tumour border 
mean ± SD 
P value* 
Age (mean ± SD) 
<53,28 
>53.28 
  
30 
39 
  
22.85 ±  20.27 
16.46 ±  21.30 
  
  
0.227 
  
51.99 ± 9.49 
34.51 ± 6.76 
  
  
0.484 
Gender 
Males 
Females 
  
9 
60 
  
20.77 ± 23.08 
19.71 ± 20.62 
  
  
0.898 
  
15.26 ±18.48 
28.17 ± 48.17 
  
  
0.467 
Pt classification 
T1-T2 
T3-T4 
  
64 
5 
  
20.82 ± 21.53 
35.23 ± 24.76 
  
  
0.177 
  
31.97 ± 46.31 
36.44 ± 71.83 
  
  
0.565 
Lymph node 
metastases 
No 
Yes 
  
  
2 
67 
  
  
30.55 ± 35.14 
22.07 ± 21.87 
  
  
  
0.385 
  
  
30.55 ± 35.14 
22.07 ± 21.87 
  
  
  
0.647 
Ptnm staging 
I=II 
III-IV 
  
62 
7 
  
20.29 ± 21.20 
33.89 ± 24.90 
  
  
0.143 
  
32.03 ± 47.56 
34.80 ± 58.76 
  
  
1.000 
Differentiation 
Well 
Poorly 
  
69 
  
26.16 ± 24.84 
  
  
1.000 
  
41.44 ± 54.90 
  
  
0.452 
Capsule 
None 
Present 
  
9 
60 
  
19.50 ± 22.32 
24.33 ± 22.38 
  
  
0.177 
  
29.98 ± 54.91 
34.58 ± 49.11 
  
  
0.937 
* Mann-Whitney  U test. 
 
Patients with low infiltration with CD68-
positive cells in tumour stroma have significantly 
shorter overall survival (median of 129.267 months) 
compared to those with high CD68-positive cells 
infiltration (median is not reached, p = 0.034, Log-rank 
test). 
 
 
Discussion 
 
Our study demonstrates that TGF-β1, 
SMAD4, SMAD7 and TGFβRII protein expression is 
observed in PTC tumour cells and these proteins are 
overexpressed in tumour cells as compared to the 
surrounding normal thyroid tissue. We couldn’t find 
any difference in the expression of TGF-β1 signalling 
proteins in tumour centre and periphery as did Eloy et 
al. (2012). Moreover, the number of patients with PTC 
is similar in both studies (75 patients in Eloy at al., 
2012; 80 patients in our study). Our PTCs are mainly 
well-circumscribed, and we don’t subdivide them to 
well-circumscribed papillary thyroid cancer (WCPTC) 
and poorly-circumscribed papillary thyroid cancer 
(PCPTC), respectively as Eloy et al., 2012 do. These 
authors establish that in WCPTCs the differences of 
TGF-β1 expression from centre to the periphery are 
very insignificant. We detect that TGF-β1, SMAD4 and 
SMAD7expression in all cases of PTC and control 
tissues (except in 17 TGF-β1 negative cases) are 
similar to that reported previously [2] [11] [18]. SMAD4 
cytoplasmic/nuclear expression is considered to be 
indicative of a functioning TGF-β (SMAD-dependent 
pathway) [11] [19]. In our study, it is demonstrated 
that all tumours expressed SMAD4 in their cytoplasm 
to a lesser extent than TGF-β1. It is known that the 
lower expression of SMAD4 was mainly responsible 
for the impairment TGF-β signalling [19]. In a previous 
study, the authors demonstrated that SMAD4 
mutations are frequent in PTC [27] when sequencing 
of the entire coding part of the SMAD4 gene was 
performed. In later study D’Inzeo et al., 2010 
hypothesised that the cause of lower expression of 
SMAD4 could be found in alteration of major 
components of translational machinery, which are 
frequently altered in human neoplasms [28]. The 
molecular mechanism that controls subcellular 
localisation and activation of Smad proteins is crucial 
for TGF-β signalling, and it is not yet fully clarified. It 
has been shown that SMAD4 nuclear expression is 
reduced in cancer [19]. However, SMAD4 undergoes 
continuous nucleocytoplasmic shuttling on its own, 
independently of TGF-β signalling [29]. The levels and 
the duration of residence in the nucleus of SMAD4 are 
important events for the response of TGF-β in the 
cells, and the intensity and duration of the TGF–β-
Smad response is important for the signalling 
specificity. There we demonstrate the reduction of 
SMAD4 protein expression in PTC tumour cell 
cytoplasm and in nuclei which may be indicative of a 
loss of TGF-β cytostatic response (loss of tumour cell 
growth inhibition). Therefore the reduction of SMAD4 
cytoplasmic and loss of nuclear protein expression is 
associated with the embarrassment of the TGF-β 
signalling pathway.SMAD7 nuclear expression was 
associated to loss of TGF–β/Smad–dependent 
pathway inhibition [2], and its expression is found to 
be at basal levels and lesser as compared to TGF-β1 
and SMAD4 expression of the cases in the presents 
series-similarly to other reports [11]. TGF-βRII mRNA 
overexpression was detected in PTC cell lines [17]. In 
our study, TGF-βRII expression was lower as 
compared to TGF-β1 expression in tumour cells of 
PTC. 
We demonstrate that all investigated from 
TGF–β/Smad pathway proteins in our study are 
associated with increased CD68 TAMs density in 
tumour stroma and the border of PTCs. It has been 
shown that large cohorts of cancers including thyroid 
cancer with high-density TAMs have poor prognoses 
and poor survival rates [30].  
 The impact of TGF-β signalling in the 
immune system was well documented. TGF-β 
promotes recruitment of monocytes, and it has been 
hypothesised that TGF-β can promote monocytes to 
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macrophage differentiation [1]. Moreover, TGF-β 
stimulation of macrophages had been shown to 
attenuate macrophages associated suppression of 
CD4
+
 T cell proliferation. TGF-β signalling is needed 
for the alternative activation of macrophages to M2 
status. It has been shown that lack of TGF-βRII leads 
to the defects in the expression of a set of genes that 
form the hallmark of the M2 polarising program [22]. 
Therefore, TGF-β enhances motility and 
stimulates recruitment of monocytes, macrophages 
and other immune cells while directly inhibiting their 
anti-tumour effector functions [31]. As a result, TGF-β 
associated inflammation can promote tumorigenesis 
due to secretion of growth-factors, cytokines, 
chemokines, etc. from the recruited immune cells that 
stimulated cancer cell growth, motility and invasion. 
 
 
References 
 
1. Bierie B, Moses HL. Transforming growth factor beta (TGF-β) 
and inflammation in cancer cytokine. Growth Factor Rev. 2010; 
21(1):4959. 
2. Eloy C, Santos J, Cameselle-Teiyeiro C, Soares P, Simoes-
Sobrinho M. TGF-beta/Smad pathway and BRAF mutation play 
different roles in circumscribed and infiltrative papillary thyroid 
carcinoma. Virchows Arch. 2012; 460:587-600. 
https://doi.org/10.1007/s00428-012-1234-y PMid:22527019  
 
3. Cunha LL, Marcello MA, Ward LS. The role of inflammatory 
microenvironment in thyroid carcinogenesis. Endocrine–Related 
Cancer. 2014; 21:R85-R103. https://doi.org/10.1530/ERC-13-0431 
PMid:24302667  
 
4. Miyazono K, Ehata S, Koinuma D. Tumor-promoting function of 
transforming growth factor β in progression of cancer. Upsala J of 
Medical Sci. 2012; 117:143-152. 
https://doi.org/10.3109/03009734.2011.638729 PMid:22111550 
PMCid:PMC3339546 
 
5. Zhang YE. Non-Smad pathway in TGF-β signaling. Cell Res. 
2009; 19(1):128-139. https://doi.org/10.1038/cr.2008.328 
PMid:19114990 PMCid:PMC2635127 
 
6. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu 
J, Pittet JF, Kaminski N, Garat C, Matthay MA, Rifkin DB, 
Sheppard D. The integrin alpha v beta 6 binds and activates latent 
TGF beta1: a mechanism for regulating pulmonary inflammation 
and fibrosis. Cell. 1999; 96(3):319-328. 
https://doi.org/10.1016/S0092-8674(00)80545-0 
 
7. Taipale J, Lohi J, Saarinen J, et al. Human mast cell chymase 
and leukocyte elastase release latent transforming growth factor-
beta 1 from the extracellular matrix of cultured human epithelial 
and endothelial cells. J Biol Chem. 1995; 270:4689–4696. 
https://doi.org/10.1074/jbc.270.9.4689 PMid:7876240  
 
8. Yu Q, Stamenkovic I. Cell surface-localized matrix 
metalloproteinase-9 proteolytically activates TGF-β and promotes 
tumor invasion and angiogenesis. Genes Dev. 2000; 14(2):163-
176. PMid:10652271 PMCid:PMC316345 
 
9. Lee MK, Pardoux C, Hall MC, Lee PS, Warburton D, Qing J, 
Smith SM, Derynck R. TGF-beta activates Erk MAP kinase 
signalling through direct phosphorylation of ShcA. Embo J. 2007; 
26(17):3957-3967. https://doi.org/10.1038/sj.emboj.7601818 
PMid:17673906 PMCid:PMC1994119 
 
10. Elliot RL, Blobe GC. Role of transforming growth factor beta in 
human cancer. J Clin Oncol. 2005; 23:2078-2093. 
https://doi.org/10.1200/JCO.2005.02.047 PMid:15774796  
 
11. Matsuo SE, Fiore AP, Siguematu SM, Ebina KN, Friguglietti 
CU, Ferro MC, Kulcsar MA, Kimura ET. Expression of SMAD 
proteins, TGF-beta/active in signaling mediators, in human thyroid 
tissues. Arq Bras Endocrinol Metab. 2010; 54: 405-412. 
https://doi.org/10.1590/S0004-27302010000400010 
 
12. Vendramini-Costa DB and Carvalho JE. Molecular link 
mechanisms between inflammation and cancer. Current 
Pharmaceutical Design. 2012; 18:3831-3852. 
https://doi.org/10.2174/138161212802083707 PMid:22632748  
 
13. Fabregat I, Fernando J, Mainez J, Sancho P. TGF-β signaling 
in cancer treatment. Current Pharmaceutical Design. 2013; 
287(4):755–63. 
 
14. Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Gorman CA, 
Maurer MS, McIver B, Mullan BP. Papillary thyroid carcinoma 
managed at the Mayo Clinic during six decades (1940–1999): 
temporal trends in initial therapy and long-term outcome in 2444 
consecutively treated patients. World J Surg. 2002; 26:879-885. 
https://doi.org/10.1007/s00268-002-6612-1 PMid:12016468  
 
15. Wang NI, Jiang R, Yang J-Y, Tang C, Yang L, Xu M, Jiang Q-
F, Lin Z-M. Expression of TGF-β1, SNAI1 and MMP-9 is 
associated with lymph node metastasis in papillary thyroid 
carcinoma. J Mol Histol. 2014; 45:391-399. 
https://doi.org/10.1007/s10735-013-9557-9 PMid:24276590  
 
16. Colleta G, Cirafici AM, Di Carlo A. Dual effect of transforming 
growth factor beta on rat thyroid cells: inhibition of thyrotropin-
induced proliferation and reduction of thyroid-specific differentiation 
markers. Cancer Res. 1989; 49(13):3457-62. 
 
17. Mincione G, Tarantelli C, Vianale G, Di Marcantonio MC, 
Cotellese R, Francomano F, Di Nicola M, Constantini E, Cichella A, 
Muraro R. Mutual regulation of TGF-β1, TβRII and ErbB receptors 
expression in human thyroid carcinomas. Exp. Cell Res. 2014; 
327:24-36. https://doi.org/10.1016/j.yexcr.2014.06.012 
PMid:24973511  
 
18. Kimura ET, Kopp P, Zbaren J, Asmis LM, Ruchti C, Maciel RM, 
Studer H. Expression of Transforming Growth Factor β1, β2, and 
β3 in Multinodular Goiters and Differentiated Thyroid Carcinomas: 
A Comparative Study. Thyroid. 1999; 9:119-125. 
https://doi.org/10.1089/thy.1999.9.119 PMid:10090310  
 
19. D'Inzeo S, Nicolussi A, Ricci A, Mancini P, Porcellini A, Nardi F, 
Coppa A. Role of reduced expression of SMAD4 in papillary thyroid 
carcinoma. J Mol Endocrinol. 2010; 45:229-244. 
https://doi.org/10.1677/JME-10-0044 PMid:20685810  
 
20. Cerutti JM, Ebina KN, Matusio SE, Martins R, Maciel RM, 
Kimura ET. Expression of Smad4 and Smad7 in human thyroid 
follicular carcinoma cell lines. J Endocrinol Invest. 2003; 26:516-
521. https://doi.org/10.1007/BF03345213 PMid:12952364  
 
21. Lazzereschi D, Ranieri A, Mincione G, Taccogna S, Nardi F, 
Colletta G. Human malignant thyroid tumors displayed reduced 
levels of transforming growth factor beta receptor type II 
messenger RNA and protein. Cancer Res. 1997; 57(10):2071-
2076. PMid:9158007  
 
22. Gong D, Shi W, Yi S-J, Chen H, Groffen J, Heisterkamp N. 
TGFβ signaling plays a critical role in promoting alternative 
macrophage activation. BMC Immunology. 2012; 13:31-41. 
https://doi.org/10.1186/1471-2172-13-31 PMid:22703233 
PMCid:PMC3406960 
 
23. Li MO, Yisong Y, Wan SS et al. Transforming-growth factor- 
beta regulation of immune responses. Annu Rev Immunol. 2006; 
24:99-146. 
https://doi.org/10.1146/annurev.immunol.24.021605.090737 
PMid:16551245  
 
24. Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Staging 
systems for papillary thyroid carcinoma: a review and comparison. 
Ann Surg. 2007; 245:366-378. 
https://doi.org/10.1097/01.sla.0000250445.92336.2a 
PMid:17435543 PMCid:PMC1877011 
 
25. DeLellis RA, Lloyd RV, Heitz PU, et al. Pathology and genetics 
of tumors of endocrine organs World Held Organization 
Clasifications of tumors. Lyon: IARC press, 2004. 
 
 Ivanova et al. GF-β1, SMAD4, SMAD7, TGFβRII and CD68-Positive TAM Densities in Papillary Thyroid Cancer  
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci.                                                                                                                                                                                                         7 
 
26. Gulubova MV, Ananiev J, Yovchev Y, Julianov A, 
Karashmalakov A, Vlaykova T. The density of macrophages in 
colorectal cancer is inversely correlated to TGF- β expression and 
patients' survival. J Mol Histol. 2013; 44:679-692. 
https://doi.org/10.1007/s10735-013-9520-9 PMid:23801404  
 
27. Lazzereschi D, Nardi F, Turco A, Ottini L, D'Amico C, Mariani-
Costantini R, Gulino A, Coppa A. A complex pattern of mutations 
and abnormal splicing of Smad4 is present in thyroid tumors. 
Oncogene. 2005; 24:5344-5354. 
https://doi.org/10.1038/sj.onc.1208603 PMid:15940269  
 
28. Rosenwald IB. The role of translation in neoplastic 
transformation from a pathologists point of view. Oncogene. 2004; 
23:3230-3247. https://doi.org/10.1038/sj.onc.1207552 
PMid:15094773  
 
29. Hill CS. Nucleocytoplasmic shuttling of Smad proteins. Cell 
Research. 2009; 19:36-46. https://doi.org/10.1038/cr.2008.325 
PMid:19114992  
 
30. Jung KY, Cho SW, Kim YA, Kim D et al. Cancers with higher 
density of tumor-associated macrophages was associated with 
poor survival rates. J Pathol Translat Med. 2015; 49:318-324. 
https://doi.org/10.4132/jptm.2015.06.01 PMid:26081823 
PMCid:PMC4508569 
 
31. Li Mo et al. Transforming growth factor beta and the immune 
responses. Annu Rev Immunol. 2006; 24; 99-146. 
https://doi.org/10.1146/annurev.immunol.24.021605.090737 
PMid:16551245  
 
 
